Revolve Wealth Partners’s 10x Genomics TXG Stock Holding History

Revolve Wealth Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$245K	Buy	+2,713	New	+$159K	0.03%	269

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return

Revolve Wealth Partners's TXG Position: Q3 2026 in Review

Revolve Wealth Partners opened a new position in 10x Genomics (TXG) in Q3 2026: 2,713 shares worth $245K. The stake represents 0.03% of the portfolio and ranks #269 among its holdings.

257 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

Revolve Wealth Partners held 2,713 shares of 10x Genomics worth $245K as of Q3 2026.
10x Genomics was a new Revolve Wealth Partners position in Q3 2026.
10x Genomics made up 0.03% of Revolve Wealth Partners's portfolio in Q3 2026, its #269 holding.
257 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Revolve Wealth Partners's 13F filing for Q3 2026, filed 23 Oct 2026.